Assessment of type I error rates for the statistical sub-model in NONMEM
- PMID: 12449498
- DOI: 10.1023/a:1020254823597
Assessment of type I error rates for the statistical sub-model in NONMEM
Abstract
The aim of this study was to assess the type I error rate when applying the likelihood ratio (LR) test, for components of the statistical sub-model in NONMEM. Data were simulated from a pharmacokinetic one compartment intravenous bolus model. Two models were fitted to the data, the simulation model and a model containing one additional parameter, and the difference in objective function values between models was calculated. The additional parameter was either (i) a covariate effect on the interindividual variability in CL or V, (ii) a covariate effect on the residual error variability, (iii) a covariance term between CL and V, or (iv) interindividual variability in V. Factors in the simulation conditions (number of individuals and samples per individual, interindividual and residual error magnitude, residual error model) were varied systematically to assess their potential influence on the type I error rate. Different estimation methods within NONMEM were tried. When the first-order conditional estimation method with interaction (FOCE INTER) was used the estimated type I error rates for inclusion of a covariate effect (i) on the interindividual variability, or (ii) on the residual error variability, were in agreement with the type I error rate expected under the assumption that the model approximations made by the estimation method are negligible. When the residual error variability was increased, the type I error rates for (iii) inclusion of covariance between etaCL-etaV were inflated if the underlying residual distribution was lognormal, or if a normal distribution was combined with too little information in the data (too few samples per subject or sampling at uninformative time-points). For inclusion of (iv) etaV, the type I error rates were affected by the underlying residual error distribution; with a normal distribution the estimated type I error rates were close to the expected, while if a non-normal distribution was used the type I errors rates increased with increasing residual variability. When the first-order (FO) estimation method was used the estimated type I error rates were higher than the expected in most situations. For the FOCE INTER method, but not the FO method, the LR test is appropriate when the underlying assumptions of normality of residuals, and of enough information in the data, hold true. Deviations from these assumptions may lead to inflated type I error rates.
Similar articles
-
Assessment of actual significance levels for covariate effects in NONMEM.J Pharmacokinet Pharmacodyn. 2001 Jun;28(3):231-52. doi: 10.1023/a:1011527125570. J Pharmacokinet Pharmacodyn. 2001. PMID: 11468939
-
Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.Clin Pharmacokinet. 2006;45(4):365-83. doi: 10.2165/00003088-200645040-00003. Clin Pharmacokinet. 2006. PMID: 16584284
-
Evaluation of type I error rates when modeling ordered categorical data in NONMEM.J Pharmacokinet Pharmacodyn. 2004 Feb;31(1):61-74. doi: 10.1023/b:jopa.0000029489.97168.a9. J Pharmacokinet Pharmacodyn. 2004. PMID: 15346852
-
The impact of misspecification of residual error or correlation structure on the type I error rate for covariate inclusion.J Pharmacokinet Pharmacodyn. 2009 Feb;36(1):81-99. doi: 10.1007/s10928-009-9112-1. Epub 2009 Feb 14. J Pharmacokinet Pharmacodyn. 2009. PMID: 19219538
-
A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.AAPS J. 2007 Mar 2;9(1):E60-83. doi: 10.1208/aapsj0901007. AAPS J. 2007. PMID: 17408237 Free PMC article. Review.
Cited by
-
Optimizing Vancomycin Dosing in Chronic Kidney Disease by Deriving and Implementing a Web-Based Tool Using a Population Pharmacokinetics Analysis.Front Pharmacol. 2019 Jun 11;10:641. doi: 10.3389/fphar.2019.00641. eCollection 2019. Front Pharmacol. 2019. PMID: 31244657 Free PMC article.
-
Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection.Antimicrob Agents Chemother. 2018 Aug 27;62(9):e00517-18. doi: 10.1128/AAC.00517-18. Print 2018 Sep. Antimicrob Agents Chemother. 2018. PMID: 29987142 Free PMC article. Clinical Trial.
-
Sample size computations for PK/PD population models.J Pharmacokinet Pharmacodyn. 2005 Dec;32(5-6):685-701. doi: 10.1007/s10928-005-0078-3. J Pharmacokinet Pharmacodyn. 2005. PMID: 16284914
-
Population pharmacokinetics of piperaquine after two different treatment regimens with dihydroartemisinin-piperaquine in patients with Plasmodium falciparum malaria in Thailand.Antimicrob Agents Chemother. 2008 Mar;52(3):1052-61. doi: 10.1128/AAC.00955-07. Epub 2008 Jan 7. Antimicrob Agents Chemother. 2008. PMID: 18180343 Free PMC article. Clinical Trial.
-
Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.Eur J Clin Pharmacol. 2007 May;63(5):437-49. doi: 10.1007/s00228-007-0269-5. Epub 2007 Mar 13. Eur J Clin Pharmacol. 2007. PMID: 17404720 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources